18F-FDG PET/CT预测接受嵌合抗原受体T细胞治疗的B细胞非霍奇金淋巴瘤患者预后:输注前与M1图像的价值
本研究纳入93例接受抗CD19 CAR-T治疗的B细胞非霍奇金淋巴瘤患者,于输注前及输注后1个月(M1)行18F-FDG PET/CT并随访。多因素分析显示M1 SUVmax是PFS和OS的独立预后因素,结外病灶数与IPI分别与PFS和OS相关;M1 PET/CT的预后价值优于输注前。
要点
- M1 SUVmax≥12.4者中位PFS短于<12.4者(1.1个月 vs 未达到,P<0.001)。
- 结外病灶≥2处者中位PFS短于<2处者(6.4个月 vs 未达到,P=0.032)。
- IPI≥3者中位OS为14.1个月,短于IPI<3者(未达到,P=0.011)。
核心结论
- 对接受CAR-T治疗的B-NHL患者,M1 PET/CT的预后价值比输注前PET/CT更重要。
- 结外病灶数和M1 SUVmax是PFS的独立危险因素,IPI和M1 SUVmax是OS的独立危险因素。
- 整合临床特征与PET/CT参数可能有助于患者管理中的早期决策。
研究设计与样本
- 收集接受CAR-T治疗且在输注前1个月及输注后1个月(M1)行18F-FDG PET/CT的B-NHL患者并定期随访。
- 记录每次PET/CT的SUVmax、MTV、TLG以及部分临床和实验室指标。
- 以PFS和OS为终点,采用Kaplan-Meier法估计。
- 共纳入93例患者,中位随访时间21.1个月。
主要发现
- 多因素分析显示结外病灶数和M1 SUVmax是PFS的独立预后因素。
- 结外病灶≥2处者中位PFS为6.4个月,短于结外病灶<2处者(未达到),P=0.032。
- M1 SUVmax≥12.4者中位PFS为1.1个月,短于SUVmax<12.4者(未达到),P<0.001。
- IPI≥3者中位OS为14.1个月,短于IPI<3者(未达到),P=0.011。
- M1 SUVmax<12.9者中位OS为未达到,长于SUVmax≥12.9者(12.0个月),P<0.001。
关键数值与推荐
- PFS的独立预后因素:结外病灶数和M1 SUVmax。
- OS的独立预后因素:IPI和M1 SUVmax。
- 结外病灶≥2处 vs <2处:中位PFS 6.4个月 vs 未达到,P=0.032。
- M1 SUVmax≥12.4 vs <12.4:中位PFS 1.1个月 vs 未达到,P<0.001。
- IPI≥3 vs <3:中位OS 14.1个月 vs 未达到,P=0.011。
临床怎么用
- 原文结论指出,整合临床特征与PET/CT参数可能有助于患者管理中的早期决策。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to evaluate the prognostic value of pre- and post-infusion 18F-FDG PET/CT for B-cell non-Hodgkin lymphoma B-NHL) patients treated with anti-CD19 chimeric antigen receptor T (CAR-T) cells. METHODS: B-NHL patients who received CAR-T therapy and underwent 18F-FDG PET/CT examination one month before (pre-infusion) and after (M1) CAR-T infusion were collected and regularly followed up. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) was recorded for each PET/CT performed, as well as some clinical and laboratory indexes. Progression-free survival (PFS) and overall survival (OS) were endpoints, estimated by the Kaplan-Meier method. RESULTS: Ninety-three patients were included. The median follow-up time was 21.1 months. Multivariate analysis showed that extranodal (EN) sites and SUVmax at M1 were independent prognostic factors for PFS. Patients with EN sites ≥ 2 had shorter median PFS than those with EN sites < 2 (6.4 months vs. not reached [NR], P = 0.032). Patients with M1 SUVmax ≥ 12.4 had shorter median PFS than those with SUVmax < 12.4 (1.1 months vs. NR, P < 0.001). Regarding OS, International Prognostic Index (IPI) and SUVmax at M1 were strongly associated with subsequent outcomes. The median OS was 14.1 months for patients with IPI ≥ 3, compared with NR for those with IPI < 3 (P = 0.011). Patients with SUVmax < 12.9 at M1 had longer median OS compared to those with SUVmax ≥ 12.9 (NR vs. 12.0 months, P < 0.001). CONCLUSION: For B-NHL patients who received CAR-T therapy, M1 PET/CT had a more important prognostic value than the pre-infusion one. EN sites and SUVmax at M1 were independent risk factors for PFS, and IPI and SUVmax at M1 for OS. Integrating the clinical characteristics and PET/CT parameters can be helpful for early decision-making in patient management. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Yao X, Wang H, Lei X, et al. 18F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image. Eur J Nucl Med Mol Imaging. 2025. PMID: 40355746. doi:10.1007/s00259-025-07302-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。